
    
      The open-label prospective randomized clinical trial compares subcutaneous LMWH
      (tinzaparin)administered for 6 months versus initial treatment using subcutaneous LMWH
      followed by oral anticoagulants given for a similar period of time in patients with proximal
      venous thrombosis.
    
  